Gain Therapeutics, Inc.
GANX evidence brief
What we can confirm
- Market Cap:
- $76.4M
What it means
What to watch
Prepared research question
What matters most for GANX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GANX
Gain Therapeutics (GANX) is a clinical-stage biotech developing brain-penetrant allosteric small molecules for neurodegenerative diseases, with its lead candidate GT-02287 (rexaceract) targeting Parkinson's disease and having received FDA IND authorization for Phase 2 development.
Key risk: Operating losses without revenue
Market Cap
$76.4M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 clinical trials for Gain Therapeutics, Inc..
Gain Therapeutics (GANX) is a clinical-stage biotech developing brain-penetrant allosteric small molecules for neurodegenerative diseases, with its lead candidate GT-02287 (rexaceract) targeting Parkinson's disease and having received FDA IND authorization for Phase 2 development.
- Cash & equivalents of $13.1M as of 2026-06-30 [sec].
- Net income of -$4.7M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $11.3M as of 2026-06-30 [sec].
- FDA authorized the IND for GT-02287 (rexaceract) on June 29, 2026, allowing Phase 2 initiation in the U.S. [sec · filed 2026-06-29].
- Cash runway is anticipated to fund operations into Q2 2027, including completion of Phase 1b open-label extension in October 2026 and Phase 2 start in Q3 2026 [news · published 2026-07-16].
What works
- FDA IND authorization for GT-02287 enables Phase 2 clinical development in the U.S., expanding from Australian sites to U.S. and European sites [sec · filed 2026-06-29].
- Phase 1b biomarker data showed participants with elevated baseline CSF glucosylsphingosine had a reduction in levels after three months of treatment and improved MDS-UPDRS Part II and III scores [sec_mda · as of 2026-08-11].
- Cash runway projected into Q2 2027, covering key near-term milestones such as Phase 1b completion and Phase 2 initiation [news · published 2026-07-16].
What to weigh
- Net loss of -$4.7M as of 2026-06-30 indicates ongoing operating losses with no approved products generating revenue [sec].
- Research and development expenses are expected to increase substantially as clinical trials progress, putting pressure on the current cash runway [sec_mda · as of 2026-08-11].
- The company faces macroeconomic risks including supply chain disruptions, liquidity concerns, and geopolitical tensions that could impact operations [sec_mda · as of 2026-03-26].
From the filings
Quoted directly from source documents.
FDA authorized IND for GT-02287 for Phase 2 in Parkinson's disease
“the U.S. Food and Drug Administration ("FDA") has authorized the Company's Investigational New Drug application for GT-02287. FDA's decision will allow initiation of the Company's Phase 2 clinical development of GT-02287 in Parkinson's disease with or without a GBA1 mutation in the U.S.”
SEC filings · June 29, 2026
Cash runway into Q2 2027
“its current cash and cash equivalents are anticipated to fund the Company's operations into the second quarter of 2027, based on current operating plans, including the completion of the Phase 1b open-label extension in October 2026 and initiation of a Phase 2 clinical study during the third quarter of 2026.”
News · July 16, 2026
Phase 1b biomarker data showing reduction in CSF glucosylsphingosine and improved MDS-UPDRS scores
“Participants with elevated baseline cerebrospinal fluid glucosylsphingosine demonstrated a reduction in levels following three months of treatment, and in the efficacy analysis they showed an improvement in combined MDS-UPDRS Part II and Part III scores compared to the rest of the participants.”
SEC MD&A · August 11, 2026
Catalyst timeline
- 2026-05-30 · Phase 2a study start for GT-02287 — A randomized, placebo-controlled, double-blind Phase 2a study to evaluate clinical efficacy, safety, tolerability, and biomarker effects of two dose levels of GT-02287 in early Parkinson's disease.
Risks & what to watch (3)›
Key risks
- Operating losses without revenue — Net loss of -$4.7M as of 2026-06-30 with no approved products generating revenue [sec].
- Rising R&D expenses — R&D expenses expected to increase substantially as clinical trials progress, potentially accelerating cash burn [sec_mda · as of 2026-08-11].
- Macroeconomic and geopolitical risks — Supply chain disruptions, liquidity concerns, and geopolitical tensions could impact operations and financing [sec_mda · as of 2026-03-26].
What to watch
- Completion of Phase 1b open-label extension in October 2026 [news · published 2026-07-16].
- Initiation of Phase 2a study of GT-02287 in Q3 2026, with enrollment across U.S., Australia, and Europe [sec_mda · as of 2026-08-11].
- Cash runway into Q2 2027 and whether additional financing is needed before then [news · published 2026-07-16].
- Further biomarker and efficacy data from ongoing Phase 1b and upcoming Phase 2 studies [sec_mda · as of 2026-08-11].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run Gain Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Gain Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 8.3%
- Days to cover
- 6.2
- Shares short
- 3,442,408
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GANX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Gain Therapeutics, Inc.?
Gain Therapeutics (GANX) is a clinical-stage biotech developing brain-penetrant allosteric small molecules for neurodegenerative diseases, with its lead candidate GT-02287 (rexaceract) targeting Parkinson's disease and having received FDA IND authorization for Phase 2 development.
Who is the CEO of Gain Therapeutics, Inc.?
Mr. Gene Mack M.B.A. is the chief executive officer of Gain Therapeutics, Inc. (GANX).
Where is Gain Therapeutics, Inc. headquartered?
Gain Therapeutics, Inc. (GANX) is headquartered in Bethesda, MD, United States.
What therapeutic areas does Gain Therapeutics, Inc. focus on?
Gain Therapeutics, Inc. develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.